What are the off‑label uses of low‑dose quetiapine (25 mg) for insomnia, sleep terrors, or anxiety symptoms?

Off-Label Use of Quetiapine 25mg for Insomnia, Sleep Terrors, or Anxiety

Quetiapine 25mg should NOT be used off-label for insomnia, sleep terrors, or anxiety symptoms due to lack of efficacy evidence and significant safety concerns including increased mortality, dementia, falls, and metabolic complications, even at low doses.

FDA-Approved Indications Only

The FDA has approved quetiapine exclusively for schizophrenia, bipolar mania, and bipolar depression at doses of 150-800 mg/day 1. The 25mg dose you're asking about is far below the therapeutic range for any FDA-approved indication and has no regulatory approval for insomnia, sleep terrors, or anxiety.

Why This Off-Label Practice Should Be Avoided

Lack of Guideline Support

Major sleep medicine guidelines explicitly do not recommend quetiapine for insomnia treatment:

• The American Academy of Sleep Medicine (2017) clinical practice guideline makes no recommendation for quetiapine in chronic insomnia, as it was not included in their evidence review 2
• The American College of Physicians (2016) guideline similarly does not include quetiapine among recommended pharmacologic treatments for insomnia 3
• These guidelines instead recommend FDA-approved agents like eszopiclone, zolpidem, suvorexant, or low-dose doxepin (3-6mg) for sleep maintenance 2

Serious Safety Concerns at Low Doses

Despite widespread off-label use, low-dose quetiapine carries substantial risks:

Mortality and Neurological Risks:

• A 2025 retrospective cohort study in older adults (≥65 years) found low-dose quetiapine increased mortality risk 3-fold compared to trazodone (HR 3.1,95% CI 1.2-8.1) 4
• 8-fold increased risk of dementia compared to trazodone (HR 8.1,95% CI 4.1-15.8) 4
• 7-fold increased risk of dementia compared to mirtazapine (HR 7.1,95% CI 3.5-14.4) 4
• 2.8-fold increased risk of falls compared to trazodone 4

Metabolic and Other Adverse Effects:

• Weight gain occurs even at low doses, with retrospective studies showing significant increases from baseline 5
• Case reports document fatal hepatotoxicity, restless legs syndrome, and akathisia at low doses 5
• Common adverse effects include somnolence (18-57%), dry mouth (9-44%), dizziness (11-18%), and orthostatic hypotension 1

Insufficient Efficacy Evidence

The evidence base for low-dose quetiapine in insomnia is extremely weak:

• A 2012 systematic review concluded: "Based on limited data and potential safety concerns, use of low-dose quetiapine for insomnia is not recommended" 5
• A 2013 review stated that "evidence for its efficacy is currently lacking" and "sufficient scientific evidence that justifies the current practice of off-label prescribing...is insufficient" 6
• While a 2023 meta-analysis showed some improvement in sleep quality (SMD: -0.57), this was primarily in patients with psychiatric disorders (GAD, MDD), not primary insomnia, and adverse events were common 7

Specific Conditions You Asked About

Insomnia

Use FDA-approved alternatives instead:

• For sleep onset: zaleplon 10mg, zolpidem 10mg, triazolam 0.25mg, or ramelteon 8mg 2
• For sleep maintenance: eszopiclone 2-3mg, zolpidem, suvorexant, or doxepin 3-6mg 2
• Consider cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment

Sleep Terrors

No evidence exists for quetiapine in sleep terrors. This parasomnia requires specialized evaluation and treatment approaches not addressed in the quetiapine literature.

Anxiety Symptoms

Quetiapine is not FDA-approved for anxiety disorders. While one review suggested potential benefit in treatment-resistant anxiety 8, this does not justify first-line or routine use given:

• Lack of guideline support
• Availability of evidence-based treatments (SSRIs, SNRIs, buspirone, CBT)
• Significant safety concerns outweigh potential benefits

Critical Clinical Pitfalls

1. The "low-dose is safer" fallacy: The 2025 study definitively shows that even low doses (25-50mg) carry serious risks in older adults 4

2. Undiagnosed sleep apnea: Many patients with insomnia have undiagnosed obstructive sleep apnea, and quetiapine's effects on breathing control are poorly understood 9

3. Metabolic monitoring neglect: Providers using low-dose quetiapine often fail to implement the metabolic monitoring required for atypical antipsychotics

4. Elderly vulnerability: The FDA label specifically warns about factors that decrease clearance in elderly patients and recommends starting at 25mg/day with slow titration for approved indications only 1—but this doesn't justify off-label insomnia use in this high-risk population

What to Do Instead

For insomnia: Start with CBT-I, then consider FDA-approved hypnotics with guideline support 3, 2

For anxiety: Use evidence-based treatments (SSRIs, SNRIs, buspirone, psychotherapy)

For sleep terrors: Refer to sleep medicine specialist for proper evaluation

If quetiapine is already prescribed: Strongly consider tapering and transitioning to evidence-based alternatives, particularly in older adults given the mortality and dementia risks 4